Bliss GVS Pharma Ltd

Know More
NSEBSE

137.157.50 (5.78%)

12:00 AM,8th Dec 2023

136.056.40 (4.94%)

12:00 AM,8th Dec 2023

BSE : 506197

NSE : BLISSGVS

Sector : Health care

ISIN Code : INE416D01022

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Dec 08 2023 | 12:00 AM IST

Market Cap (₹ Cr)

1431

Turnover (₹ Cr)

0.96

Volume (Shares)

700854

Face Value

1

52-WK High

149.60

52-WK High Date

28 Nov 2023

52-WK Low

69.20

52-WK Low Date

29 Mar 2023

All Time High

221.00

All Time High Date

30 Dec 2020

All Time Low

18.80

All Time Low Date

03 Oct 2011

Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial antifungal antibacterial anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India.The company has a dedicated the R&D Centre for development of Suppositories Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR) Government of India.Incorporated in 1984 as a private limited company under the name Bliss Chemicals & Pharmaceuticals India Ltd the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014 Bliss GVS Pharma's R&D center received approval from Government of India's Department for Scientific & Industrial Research (DSIR).During the year under review the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review Bliss GVS Pharma faced challenges in Ghana where delays in registration resulted in adverse regulatory action. However the company took quick corrective measures to resolve these issues. The business is now backing on track in Ghana.During the year ended 31 March 2015 Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent.During the financial year ended 31 March 2016 Bliss GVS Pharma continued to grow in various geographies in Kenya Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria. Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017The company's investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. This presents a great platform for the unit to build on its recent success to successfully bid for other such contracts. During the year ended 31 March 2018 Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited Nairobi to focus on its core pharmaceutical operations which have been a steady source of growth.As on 31 March 2019the company has one domestic and 3 overseas subsidiaries.During the FY2020the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state-of-the-art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200000 sq. ft. and is intended to further augment the production capacities for the Company. The Company has 4 wholly owned subsidiaries and 3 step-down subsidiaries as on 31 March 2020. During the year ECO Rich Cosmetics India Private Limited discontinued or ceased to be a step-down subsidiary of the Company consequent to loss of control. The Company's wholly owned subsidiary Bliss GVS Clinic HealthCare Pte. Ltd. situated at Singapore became a material subsidiary for the Company during the financial year 2019-2020.

Bliss GVS Pharma Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

1431

EPS - TTM (₹) [S]

7.35

P/E Ratio (X) [S]

1.46

Face Value (₹) 1
Latest Dividend (%)50.00
Latest Dividend Date 12 Jul 2023
Dividend Yield (%) 0.37
Book Value Share (₹) [S]93.64
P/B Ratio (₹) [S]1.46
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Motilal Oswal S&P BSE Healthcare ETF 0.01 596 0.06

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

128.15

140.50

Week Low/High

127.10

149.00

Month Low/High

110.00

150.00

Year Low/High

69.20

150.00

All time Low/High

0.04

221.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-3.01%-2.83%3.473.46%
1 Month19.51%19.52%7.467.85%
3 Month42.86%42.86%4.845.80%
6 Month83.85%83.85%11.1012.53%
1 Year84.71%85.09%11.5912.68%
3 Year-23.38%-23.34%53.1056.57%

Company Info

Company Information

Whole-time Director : Vibha G Sharma

Whole-time Director : Shruti Vishal Rao

Chairman & Independent Directo : Subramanian R Vaidya

Non-Exec. & Independent Dir. : Santosh Parab

Company Sec. & Compli. Officer : Aditi Bhatt

Non-Exec. & Independent Dir. : Shilpa Bhatia

Managing Director : Gagan Harsh Sharmma

Registered Office: 102 Hyde Park Sakivihar Road, Andheri East,Mumbai,Maharashtra-400072 Ph: 91-22-42160000

Email:info@blissgvs.com

URL:http://www.blissgvs.com